Ifinatamab deruxtecan has been granted Breakthrough Therapy Designation by the FDA for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. Ifinatamab deruxtecan is a specifically engineered, potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and Merck (MRK).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Trump Weekly: Trump weighs stake in Intel, candidates for Fed Chair
- Trump Trade: Pharma tariff announcement likely ‘weeks away’
- Pharma tariff announcement likely ‘weeks away,’ Reuters reports
- Merck call volume above normal and directionally bullish
- Merck announces topline results from KEYNOTE-905 trial